Loading...
•
Jun 30, 2020
Atara Q2 2020 Earnings Report
Announced second quarter 2020 financial results and operational progress.
Key Takeaways
Atara Biotherapeutics reported a net loss of $77.5 million, or $1.14 per share, for the second quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $347.7 million as of June 30, 2020, which is expected to fund planned operations into 2022. The company is on track to initiate a BLA submission for tab-cel® for patients with EBV+ PTLD by the end of 2020.
Remains on track to initiate a BLA submission for tab-cel® for patients with EBV+ PTLD by the end of 2020.
Reported positive ATA188 clinical data in progressive multiple sclerosis.
Successfully completed a follow-on financing.
Progressing CAR T programs closer to the clinic.
Atara
Atara
Forward Guidance
Atara believes that its cash, cash equivalents and short-term investments as of June 30, 2020 are sufficient to fund planned operations into 2022.